Related Experiment Video

Updated: Nov 10, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

791

Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait

Alessandro Rizzo1, Angela Dalia Ricci1, Giovanni Brandi1

  • 1Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italia.

Immunotherapy
|April 6, 2021
PubMed

Insights

Atezolizumab plus bevacizumab offers a new standard of care for advanced hepatocellular carcinoma (HCC), significantly improving outcomes compared to sorafenib. This combination therapy marks a breakthrough in treating this challenging liver cancer. Keywords: advanced HCC, atezolizumab, bevacizumab, standard of care.

Area of Science:

  • Hepatocellular Carcinoma (HCC) treatment
  • Immunotherapy in oncology
  • Drug development for liver cancer

Background:

  • Advanced HCC historically has a poor prognosis with limited treatment options.
  • The emergence of immune checkpoint inhibitors has opened new therapeutic avenues.
  • A decade of stagnation in HCC treatment has been overcome by novel therapies.

Purpose of the Study:

  • To review the development and impact of atezolizumab in advanced HCC.
  • To summarize the mechanism of action and pharmacokinetics of atezolizumab.
  • To present evidence from Phase I to III clinical trials of atezolizumab in HCC.

Main Methods:

  • Review of clinical trial data (Phase I-III) for atezolizumab in advanced HCC.
  • Analysis of the IMbrave150 Phase III trial comparing atezolizumab plus bevacizumab to sorafenib.
  • Examination of the mechanism of action and pharmacokinetic properties of atezolizumab.

Main Results:

  • Atezolizumab in combination with bevacizumab demonstrated unprecedented results in treatment-naive patients with unresectable HCC.
  • The IMbrave150 trial showed superiority of the atezolizumab-bevacizumab combination over sorafenib monotherapy.
  • This combination has established a new standard of care for advanced HCC.

Conclusions:

  • Atezolizumab plus bevacizumab represents a significant advancement in the treatment of advanced HCC.
  • The findings establish a new benchmark for therapy in this patient population.
  • Further understanding of atezolizumab's role in HCC is crucial for optimizing patient outcomes.
Keywords:
HCCatezolizumabhepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
273
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816